Preclinical studies have shown that HDAC inhibitors (HDACis) exhibit antitumor activity against non-small lung cancer (NSCLC) cell lines by inducing apoptotic pathways [4,5]. Here, HDAC9 is linked to non-small cell lung carcinoma.